NEUP Neuphoria Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—
Leverage & solvency
Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.17M | $15.65M |
| R&D expense | — | $9.01M |
| SG&A expense | $7.44M | $7.77M |
| Operating income | -$16.45M | -$1.13M |
| Pretax income | -$13.59M | -$837,998 |
| Income tax | -$139,173 | -$468,366 |
| Net income | -$13.45M | -$369,632 |
| EBITDA | -$15.79M | -$466,201 |
| EPS (basic) | -3.06 | -0.23 |
| EPS (diluted) | -3.06 | -0.23 |
| Weighted avg. shares (diluted) | 4.40M | 1.62M |
| Balance sheet | ||
| Cash & equivalents | $19.87M | $14.29M |
| Receivables | $813,431 | $11,948 |
| Current assets | $21.07M | $15.04M |
| PP&E, net | — | $2,771 |
| Goodwill | $3.50M | $8.64M |
| Intangibles | $4.14M | $4.80M |
| Total assets | $28.71M | $28.59M |
| Current liabilities | $756,581 | $4.22M |
| Total liabilities | $4.11M | $9.59M |
| Shareholders' equity | $24.60M | $19.00M |
| Shares outstanding | 5.41M | 1.98M |
| Cash flow statement | ||
| Operating cash flow | -$12.35M | $77,229 |
| Financing cash flow | $17.92M | $1.53M |
| Depreciation & amortization | $662,955 | $662,890 |
| Stock-based compensation | $351,600 | $163,772 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.